UNION therapeutics presents new data on orismilast at the 31[st] EADV Congress supporting orismilast’s potential as a first-in-class or best-in-class treatment for certain immunological diseases
· Preclinical data presented in the oral presentation demonstrate that orismilast is a potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are considered more relevant in the treatment of immunological diseases · Phase 2a data support development of orismilast modified release (MR) tablet to improve the tolerability of orismilast which had demonstrated proof of concept in moderate to severe psoriasis in an immediate release (IR) tablet · Data presented at EADV support orismilast potential as a first-in-class